3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Conditions
Vascular Calcification
1
Neoplasm Metastasis
1
Kidney Diseases
1
Hyperparathyroidism
1
Chronic Kidney Disease-Mineral and Bone Disorder
1
Bone Diseases
1
Interventions
Cisplatin
1041
Cyclophosphamide
973
Carboplatin
954
Radiotherapy
893
Bevacizumab
847
Gemcitabine
817
pembrolizumab
759
Paclitaxel
738
Docetaxel
734
Oxaliplatin
706
Capecitabine
648
Fluorouracil
564
Rituximab
559
Nivolumab
506
Dexamethasone
487
Etoposide
468
Doxorubicin
458
Irinotecan
442
Drug Therapy
402
Leucovorin
377
Cytarabine
342
Cetuximab
340
Lenalidomide
326
Trastuzumab
323
Pemetrexed
315
durvalumab
295
Filgrastim
287
Magnetic Resonance Spectroscopy
278
Temozolomide
275
Prednisone
273
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
OTHER
×
etelcalcetide hydrochloride
×
Clear all
NCT03960437
2023-09-21
Parsabiv-MBD
Columbia University
Phase 2
Completed
22 enrolled
14 charts